Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLITION: Oral DTG/3TC Followed by Optional Switch to CAB+RPV LA in HIV-1
NCT05917509Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of dolutegravir, lamivudine, cabotegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Jul 2023; status: completed.
02
Drugs
dolutegravirlamivudinecabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05917509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917509.